2024
Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study
Neto F, Hitchings M, Amin A, de França G, Lind M, Torres M, Tsuha D, de Oliveira R, Cummings D, Dean N, Andrews J, Ko A, Croda J, Ranzani O. Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study. The Lancet Regional Health - Americas 2024, 34: 100755. PMID: 38737773, PMCID: PMC11087726, DOI: 10.1016/j.lana.2024.100755.Peer-Reviewed Original ResearchSevere COVID-19Cohort ACohort B.Cohort BTwo-doseMRNA vaccinesPrimary outcomeBooster dose effectivenessCOVID-19 outcomesPopulation-based cohort studyDose of COVID-19 vaccinePopulation-based cohortPopulation-based cohort of individualsCOVID-19 vaccine dosesSevere COVID-19 outcomesFollow-upCohort studyMRNA-basedVaccine doseCohort of individualsVaccine effectivenessVaccine combinationsDoseLower hazardCohort
2023
Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients
Diray-Arce J, Fourati S, Jayavelu N, Patel R, Maguire C, Chang A, Dandekar R, Qi J, Lee B, van Zalm P, Schroeder A, Chen E, Konstorum A, Brito A, Gygi J, Kho A, Chen J, Pawar S, Gonzalez-Reiche A, Hoch A, Milliren C, Overton J, Westendorf K, Network I, Abraham J, Adkisson M, Albert M, Torres L, Alvarenga B, Anderson M, Anderson E, Arnett A, Asashima H, Atkinson M, Baden L, Barton B, Beach K, Beagle E, Becker P, Bell M, Bernui M, Bime C, Kumar A, Booth L, Borresen B, Brakenridge S, Bristow L, Bryant R, Calfee C, Manuel J, Carrillo S, Chak S, Chang I, Connors J, Conway M, Corry D, Cowan D, Croen B, Dela Cruz C, Cusimano G, Eaker L, Edwards C, Ehrlich L, Elashoff D, Erickson H, Erle D, Farhadian S, Farrugia K, Fatou B, Fernandes A, Fernandez-Sesma A, Fragiadakis G, Furukawa S, Geltman J, Ghale R, Bermúdez M, Goonewardene M, Sanchez E, Guirgis F, Hafler D, Hamilton S, Harris P, Nemati A, Hendrickson C, Agudelo N, Hodder T, Holland S, Hough C, Huerta C, Hurley K, Hutton S, Iwasaki A, Jauregui A, Jha M, Johnson B, Joyner D, Kangelaris K, Kelly G, Khalil Z, Khan Z, Kheradmand F, Kim J, Kimura H, Ko A, Kohr B, Kraft M, Krummel M, Kutzler M, Lasky-Su J, Lee S, Lee D, Leipold M, Lentucci C, Leroux C, Lin E, Liu S, Love C, Lu Z, Maliskova L, Roth B, Manohar M, Martens M, McComsey G, McEnaney K, McLin R, Melamed E, Melnyk N, Mendez K, Messer W, Metcalf J, Michelotti G, Mick E, Mohanty S, Mosier J, Mulder L, Murphy M, Nadeau K, Nelson E, Nelson A, Nguyen V, Oberhaus J, Panganiban B, Pellegrini K, Pickering H, Powell D, Presnell S, Pulendran B, Rahman A, Sadeed A, Raskin A, Reed E, Pereira S, Rivera A, Rogers J, Rogers A, Rogowski B, Rooks R, Rosenberg-Hasson Y, Rothman J, Rousseau J, Salehi-Rad R, Saluvan M, Samaha H, Schaenman J, Schunk R, Semenza N, Sen S, Sevransky J, Seyfert-Margolis V, Shaheen T, Shaw A, Sieg S, Siegel S, Sigal N, Siles N, Simmons B, Simon V, Singh G, Sinko L, Smith C, Smolen K, Song L, Srivastava K, Sullivan P, Syphurs C, Tcheou J, Tegos G, Tharp G, Ally A, Tsitsiklis A, Ungaro R, Vaysman T, Viode A, Vita R, Wang X, Ward A, Ward D, Willmore A, Woloszczuk K, Wong K, Woodruff P, Xu L, van Haren S, van de Guchte A, Zhao Y, Cairns C, Rouphael N, Bosinger S, Kim-Schulze S, Krammer F, Rosen L, Grubaugh N, van Bakel H, Wilson M, Rajan J, Steen H, Eckalbar W, Cotsapas C, Langelier C, Levy O, Altman M, Maecker H, Montgomery R, Haddad E, Sekaly R, Esserman D, Ozonoff A, Becker P, Augustine A, Guan L, Peters B, Kleinstein S. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients. Cell Reports Medicine 2023, 4: 101079. PMID: 37327781, PMCID: PMC10203880, DOI: 10.1016/j.xcrm.2023.101079.Peer-Reviewed Original ResearchConceptsDisease courseFatal COVID-19 diseaseHospitalized COVID-19 patientsSevere disease courseCOVID-19 participantsCOVID-19 patientsTrajectory groupsHost immune responseCOVID-19 diseaseImmune correlatesAcute infectionClinical courseHospital admissionClinical outcomesFatal outcomeClinical prognosisImmune responseSevere diseaseLongitudinal bloodNasal samplesBiologic stateLongitudinal studyDistinct assaysCohortMolecular signatures
2022
Reliable estimation of SARS-CoV-2 anti-spike protein IgG titers from single dilution optical density values in serologic surveys
Belitardo E, Nery N, Ticona J, Portilho MM, Mello IO, Ribeiro GS, Reis MG, Costa F, Cummings DAT, Ko AI, Fofana MO. Reliable estimation of SARS-CoV-2 anti-spike protein IgG titers from single dilution optical density values in serologic surveys. Diagnostic Microbiology And Infectious Disease 2022, 104: 115807. PMID: 36162285, PMCID: PMC9428330, DOI: 10.1016/j.diagmicrobio.2022.115807.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 incidenceCommunity-based cohortPopulation-level immunitySARS-CoV-2Large-scale serosurveysELISA optical densityIgG titersIgG ELISAPandemic evolvesSerologic surveyTitersOptical density valuesPopulation-level changesSerosurveyImmunitySingle dilutionSerial dilutionsNODCohortIncidenceELISASerum
2021
Developmental outcomes in children exposed to Zika virus in utero from a Brazilian urban slum cohort study
Ticona J, Nery N, Ladines-Lim JB, Gambrah C, Sacramento G, de Paula Freitas B, Bouzon J, Oliveira-Filho J, Borja A, Adhikarla H, Montoya M, Chin A, Wunder EA, Ballalai V, Vieira C, Belfort R, Almeida A, Reis MG, Harris E, Ko AI, Costa F. Developmental outcomes in children exposed to Zika virus in utero from a Brazilian urban slum cohort study. PLOS Neglected Tropical Diseases 2021, 15: e0009162. PMID: 33544730, PMCID: PMC7891708, DOI: 10.1371/journal.pntd.0009162.Peer-Reviewed Original ResearchConceptsPopulation attributable fractionZIKV exposureMonths of ageMild cognitive delayZika virus exposureZIKV-exposed childrenPopulation-based cohortCognitive delayDevelopmental alterationsMonoclonal antibody blockadeMonths of lifeGross birth defectsAppropriate control groupsProspective serosurveyCohort studyNeurodevelopmental outcomesAntibody blockadeNeurodevelopmental evaluationVirus exposureAttributable fractionBehavioral abnormalitiesControl groupRest of womenZika virusCohortRisk of Sexually Transmitted Zika Virus in a Cohort of Economically Disadvantaged Urban Residents
Ticona J, Baig H, Nery N, Doss-Gollin S, Sacramento GA, Adhikarla H, Muenker MC, Wunder EA, Nascimento EJM, Marques ETA, Reis MG, Ko AI, Costa F. Risk of Sexually Transmitted Zika Virus in a Cohort of Economically Disadvantaged Urban Residents. The Journal Of Infectious Diseases 2021, 224: 860-864. PMID: 33395487, PMCID: PMC8522079, DOI: 10.1093/infdis/jiab001.Peer-Reviewed Original Research
2019
Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region
Rodriguez-Barraquer I, Costa F, Nascimento EJM, Nery N, Castanha PMS, Sacramento GA, Cruz J, Carvalho M, De Olivera D, Hagan JE, Adhikarla H, Wunder EA, Coêlho DF, Azar SR, Rossi SL, Vasilakis N, Weaver SC, Ribeiro GS, Balmaseda A, Harris E, Nogueira ML, Reis MG, Marques ETA, Cummings DAT, Ko AI. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science 2019, 363: 607-610. PMID: 30733412, PMCID: PMC8221194, DOI: 10.1126/science.aav6618.Peer-Reviewed Original ResearchConceptsZika virusZIKV NS1 antigenAttack rateZika virus emergenceHigh antibody titersDengue-endemic regionsZIKV immunityClinical outcomesDengue immunityZIKV infectionAntibody titersNS1 antigenRisk factorsEndemic regionsDengue virusImmunityVirusRiskVirus emergenceFuture transmissionCohortSymptomsInfectionAntigenTiters